Latest Articles

Publication Date
All News Scientific
Faeth Therapeutics and The GOG Foundation, Inc. (GOG-F) Launch First Phase 2 Combination Trial for Sapanisertib-Serabelisib in Patients With Endometrial Cancer - Business Wire

Faeth Therapeutics and The GOG Foundation, Inc. (GOG-F) Launch First Phase 2 Combination Trial for Sapanisertib-Serabelisib in Patients With Endometrial Cancer Business Wire

Published: March 12, 2025, 5:34 p.m.
Read Full Article
Lisata Therapeutics Inc (LSTA) Q4 2024 Earnings Call Highlights: Promising Developments Amid ... - Yahoo Finance

Lisata Therapeutics Inc (LSTA) Q4 2024 Earnings Call Highlights: Promising Developments Amid ... Yahoo Finance

Published: Feb. 28, 2025, 7:35 a.m.
Read Full Article
Lisata Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update - Yahoo Finance

Lisata Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update Yahoo Finance

Published: Feb. 27, 2025, 9:05 p.m.
Read Full Article
Karyopharm Therapeutics Inc. SEC 10-K Report - TradingView

Karyopharm Therapeutics Inc. SEC 10-K Report TradingView

Published: Feb. 19, 2025, 12:38 p.m.
Read Full Article
Acrivon Therapeutics Announces FDA has Granted Breakthrough - GlobeNewswire

Acrivon Therapeutics Announces FDA has Granted Breakthrough GlobeNewswire

Published: Feb. 5, 2025, 1:19 p.m.
Read Full Article
Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Endometrial Cancer - The Manila Times

Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Endometrial Cancer The Manila Times

Published: Feb. 5, 2025, 1:07 p.m.
Read Full Article
Repare Therapeutics eyes Phase III cancer study after Mythic trial success - MSN

Repare Therapeutics eyes Phase III cancer study after Mythic trial success MSN

Published: Jan. 14, 2025, 11:17 a.m.
Read Full Article
Repare Therapeutics eyes Phase III cancer study after Mythic trial success - Yahoo Finance

Repare Therapeutics eyes Phase III cancer study after Mythic trial success Yahoo Finance

Published: Dec. 13, 2024, 3:28 p.m.
Read Full Article
Press Release Service: Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial - CRISPR Medicine News

Press Release Service: Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial CRISPR Medicine News

Published: Dec. 13, 2024, 12:56 p.m.
Read Full Article
Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial - BioSpace

Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial BioSpace

Published: Dec. 12, 2024, 11:25 p.m.
Read Full Article
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!